Cargando…

Accuracy of high-risk HPV DNA PCR, p16((INK4a)) immunohistochemistry or the combination of both to diagnose HPV-driven oropharyngeal cancer

BACKGROUND: The incidence of high-risk human papillomavirus (hrHPV)-driven head and neck squamous cell carcinoma, in particular oropharyngeal cancers (OPC), is increasing in high-resource countries. Patients with HPV-induced cancer respond better to treatment and consequently have lower case-fatalit...

Descripción completa

Detalles Bibliográficos
Autores principales: Simoens, Cindy, Gheit, Tarik, Ridder, Ruediger, Gorbaslieva, Ivana, Holzinger, Dana, Lucas, Eric, Rehm, Susanne, Vermeulen, Peter, Lammens, Martin, Vanderveken, Olivier M., Kumar, Rekha Vijay, Gangane, Nitin, Caniglia, Alessandro, Maffini, Fausto, Rubio, Maria Belén Lloveras, Anantharaman, Devasena, Chiocca, Susanna, Brennan, Paul, Pillai, Madhavan Radhakrishna, Sankaranarayanan, Rengaswamy, Bogers, Johannes, Pawlita, Michael, Tommasino, Massimo, Arbyn, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357318/
https://www.ncbi.nlm.nih.gov/pubmed/35933382
http://dx.doi.org/10.1186/s12879-022-07654-2
_version_ 1784763685069127680
author Simoens, Cindy
Gheit, Tarik
Ridder, Ruediger
Gorbaslieva, Ivana
Holzinger, Dana
Lucas, Eric
Rehm, Susanne
Vermeulen, Peter
Lammens, Martin
Vanderveken, Olivier M.
Kumar, Rekha Vijay
Gangane, Nitin
Caniglia, Alessandro
Maffini, Fausto
Rubio, Maria Belén Lloveras
Anantharaman, Devasena
Chiocca, Susanna
Brennan, Paul
Pillai, Madhavan Radhakrishna
Sankaranarayanan, Rengaswamy
Bogers, Johannes
Pawlita, Michael
Tommasino, Massimo
Arbyn, Marc
author_facet Simoens, Cindy
Gheit, Tarik
Ridder, Ruediger
Gorbaslieva, Ivana
Holzinger, Dana
Lucas, Eric
Rehm, Susanne
Vermeulen, Peter
Lammens, Martin
Vanderveken, Olivier M.
Kumar, Rekha Vijay
Gangane, Nitin
Caniglia, Alessandro
Maffini, Fausto
Rubio, Maria Belén Lloveras
Anantharaman, Devasena
Chiocca, Susanna
Brennan, Paul
Pillai, Madhavan Radhakrishna
Sankaranarayanan, Rengaswamy
Bogers, Johannes
Pawlita, Michael
Tommasino, Massimo
Arbyn, Marc
author_sort Simoens, Cindy
collection PubMed
description BACKGROUND: The incidence of high-risk human papillomavirus (hrHPV)-driven head and neck squamous cell carcinoma, in particular oropharyngeal cancers (OPC), is increasing in high-resource countries. Patients with HPV-induced cancer respond better to treatment and consequently have lower case-fatality rates than patients with HPV-unrelated OPC. These considerations highlight the importance of reliable and accurate markers to diagnose truly HPV-induced OPC. METHODS: The accuracy of three possible test strategies, i.e. (a) hrHPV DNA PCR (DNA), (b) p16((INK4a)) immunohistochemistry (IHC) (p16), and (c) the combination of both tests (considering joint DNA and p16 positivity as positivity criterion), was analysed in tissue samples from 99 Belgian OPC patients enrolled in the HPV-AHEAD study. Presence of HPV E6*I mRNA (mRNA) was considered as the reference, indicating HPV etiology. RESULTS: Ninety-nine OPC patients were included, for which the positivity rates were 36.4%, 34.0% and 28.9% for DNA, p16 and mRNA, respectively. Ninety-five OPC patients had valid test results for all three tests (DNA, p16 and mRNA). Using mRNA status as the reference, DNA testing showed 100% (28/28) sensitivity, and 92.5% (62/67) specificity for the detection of HPV-driven cancer. p16 was 96.4% (27/28) sensitive and equally specific (92.5%; 62/67). The sensitivity and specificity of combined p16 + DNA testing was 96.4% (27/28) and 97.0% (65/67), respectively. In this series, p16 alone and combined p16 + DNA missed 1 in 28 HPV driven cancers, but p16 alone misclassified 5 in 67 non-HPV driven as positive, whereas combined testing would misclassify only 2 in 67. CONCLUSIONS: Single hrHPV DNA PCR and p16((INK4a)) IHC are highly sensitive but less specific than using combined testing to diagnose HPV-driven OPC patients. Disease prognostication can be encouraged based on this combined test result. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-022-07654-2.
format Online
Article
Text
id pubmed-9357318
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-93573182022-08-08 Accuracy of high-risk HPV DNA PCR, p16((INK4a)) immunohistochemistry or the combination of both to diagnose HPV-driven oropharyngeal cancer Simoens, Cindy Gheit, Tarik Ridder, Ruediger Gorbaslieva, Ivana Holzinger, Dana Lucas, Eric Rehm, Susanne Vermeulen, Peter Lammens, Martin Vanderveken, Olivier M. Kumar, Rekha Vijay Gangane, Nitin Caniglia, Alessandro Maffini, Fausto Rubio, Maria Belén Lloveras Anantharaman, Devasena Chiocca, Susanna Brennan, Paul Pillai, Madhavan Radhakrishna Sankaranarayanan, Rengaswamy Bogers, Johannes Pawlita, Michael Tommasino, Massimo Arbyn, Marc BMC Infect Dis Research BACKGROUND: The incidence of high-risk human papillomavirus (hrHPV)-driven head and neck squamous cell carcinoma, in particular oropharyngeal cancers (OPC), is increasing in high-resource countries. Patients with HPV-induced cancer respond better to treatment and consequently have lower case-fatality rates than patients with HPV-unrelated OPC. These considerations highlight the importance of reliable and accurate markers to diagnose truly HPV-induced OPC. METHODS: The accuracy of three possible test strategies, i.e. (a) hrHPV DNA PCR (DNA), (b) p16((INK4a)) immunohistochemistry (IHC) (p16), and (c) the combination of both tests (considering joint DNA and p16 positivity as positivity criterion), was analysed in tissue samples from 99 Belgian OPC patients enrolled in the HPV-AHEAD study. Presence of HPV E6*I mRNA (mRNA) was considered as the reference, indicating HPV etiology. RESULTS: Ninety-nine OPC patients were included, for which the positivity rates were 36.4%, 34.0% and 28.9% for DNA, p16 and mRNA, respectively. Ninety-five OPC patients had valid test results for all three tests (DNA, p16 and mRNA). Using mRNA status as the reference, DNA testing showed 100% (28/28) sensitivity, and 92.5% (62/67) specificity for the detection of HPV-driven cancer. p16 was 96.4% (27/28) sensitive and equally specific (92.5%; 62/67). The sensitivity and specificity of combined p16 + DNA testing was 96.4% (27/28) and 97.0% (65/67), respectively. In this series, p16 alone and combined p16 + DNA missed 1 in 28 HPV driven cancers, but p16 alone misclassified 5 in 67 non-HPV driven as positive, whereas combined testing would misclassify only 2 in 67. CONCLUSIONS: Single hrHPV DNA PCR and p16((INK4a)) IHC are highly sensitive but less specific than using combined testing to diagnose HPV-driven OPC patients. Disease prognostication can be encouraged based on this combined test result. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-022-07654-2. BioMed Central 2022-08-06 /pmc/articles/PMC9357318/ /pubmed/35933382 http://dx.doi.org/10.1186/s12879-022-07654-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Simoens, Cindy
Gheit, Tarik
Ridder, Ruediger
Gorbaslieva, Ivana
Holzinger, Dana
Lucas, Eric
Rehm, Susanne
Vermeulen, Peter
Lammens, Martin
Vanderveken, Olivier M.
Kumar, Rekha Vijay
Gangane, Nitin
Caniglia, Alessandro
Maffini, Fausto
Rubio, Maria Belén Lloveras
Anantharaman, Devasena
Chiocca, Susanna
Brennan, Paul
Pillai, Madhavan Radhakrishna
Sankaranarayanan, Rengaswamy
Bogers, Johannes
Pawlita, Michael
Tommasino, Massimo
Arbyn, Marc
Accuracy of high-risk HPV DNA PCR, p16((INK4a)) immunohistochemistry or the combination of both to diagnose HPV-driven oropharyngeal cancer
title Accuracy of high-risk HPV DNA PCR, p16((INK4a)) immunohistochemistry or the combination of both to diagnose HPV-driven oropharyngeal cancer
title_full Accuracy of high-risk HPV DNA PCR, p16((INK4a)) immunohistochemistry or the combination of both to diagnose HPV-driven oropharyngeal cancer
title_fullStr Accuracy of high-risk HPV DNA PCR, p16((INK4a)) immunohistochemistry or the combination of both to diagnose HPV-driven oropharyngeal cancer
title_full_unstemmed Accuracy of high-risk HPV DNA PCR, p16((INK4a)) immunohistochemistry or the combination of both to diagnose HPV-driven oropharyngeal cancer
title_short Accuracy of high-risk HPV DNA PCR, p16((INK4a)) immunohistochemistry or the combination of both to diagnose HPV-driven oropharyngeal cancer
title_sort accuracy of high-risk hpv dna pcr, p16((ink4a)) immunohistochemistry or the combination of both to diagnose hpv-driven oropharyngeal cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357318/
https://www.ncbi.nlm.nih.gov/pubmed/35933382
http://dx.doi.org/10.1186/s12879-022-07654-2
work_keys_str_mv AT simoenscindy accuracyofhighriskhpvdnapcrp16ink4aimmunohistochemistryorthecombinationofbothtodiagnosehpvdrivenoropharyngealcancer
AT gheittarik accuracyofhighriskhpvdnapcrp16ink4aimmunohistochemistryorthecombinationofbothtodiagnosehpvdrivenoropharyngealcancer
AT ridderruediger accuracyofhighriskhpvdnapcrp16ink4aimmunohistochemistryorthecombinationofbothtodiagnosehpvdrivenoropharyngealcancer
AT gorbaslievaivana accuracyofhighriskhpvdnapcrp16ink4aimmunohistochemistryorthecombinationofbothtodiagnosehpvdrivenoropharyngealcancer
AT holzingerdana accuracyofhighriskhpvdnapcrp16ink4aimmunohistochemistryorthecombinationofbothtodiagnosehpvdrivenoropharyngealcancer
AT lucaseric accuracyofhighriskhpvdnapcrp16ink4aimmunohistochemistryorthecombinationofbothtodiagnosehpvdrivenoropharyngealcancer
AT rehmsusanne accuracyofhighriskhpvdnapcrp16ink4aimmunohistochemistryorthecombinationofbothtodiagnosehpvdrivenoropharyngealcancer
AT vermeulenpeter accuracyofhighriskhpvdnapcrp16ink4aimmunohistochemistryorthecombinationofbothtodiagnosehpvdrivenoropharyngealcancer
AT lammensmartin accuracyofhighriskhpvdnapcrp16ink4aimmunohistochemistryorthecombinationofbothtodiagnosehpvdrivenoropharyngealcancer
AT vandervekenolivierm accuracyofhighriskhpvdnapcrp16ink4aimmunohistochemistryorthecombinationofbothtodiagnosehpvdrivenoropharyngealcancer
AT kumarrekhavijay accuracyofhighriskhpvdnapcrp16ink4aimmunohistochemistryorthecombinationofbothtodiagnosehpvdrivenoropharyngealcancer
AT ganganenitin accuracyofhighriskhpvdnapcrp16ink4aimmunohistochemistryorthecombinationofbothtodiagnosehpvdrivenoropharyngealcancer
AT canigliaalessandro accuracyofhighriskhpvdnapcrp16ink4aimmunohistochemistryorthecombinationofbothtodiagnosehpvdrivenoropharyngealcancer
AT maffinifausto accuracyofhighriskhpvdnapcrp16ink4aimmunohistochemistryorthecombinationofbothtodiagnosehpvdrivenoropharyngealcancer
AT rubiomariabelenlloveras accuracyofhighriskhpvdnapcrp16ink4aimmunohistochemistryorthecombinationofbothtodiagnosehpvdrivenoropharyngealcancer
AT anantharamandevasena accuracyofhighriskhpvdnapcrp16ink4aimmunohistochemistryorthecombinationofbothtodiagnosehpvdrivenoropharyngealcancer
AT chioccasusanna accuracyofhighriskhpvdnapcrp16ink4aimmunohistochemistryorthecombinationofbothtodiagnosehpvdrivenoropharyngealcancer
AT brennanpaul accuracyofhighriskhpvdnapcrp16ink4aimmunohistochemistryorthecombinationofbothtodiagnosehpvdrivenoropharyngealcancer
AT pillaimadhavanradhakrishna accuracyofhighriskhpvdnapcrp16ink4aimmunohistochemistryorthecombinationofbothtodiagnosehpvdrivenoropharyngealcancer
AT sankaranarayananrengaswamy accuracyofhighriskhpvdnapcrp16ink4aimmunohistochemistryorthecombinationofbothtodiagnosehpvdrivenoropharyngealcancer
AT bogersjohannes accuracyofhighriskhpvdnapcrp16ink4aimmunohistochemistryorthecombinationofbothtodiagnosehpvdrivenoropharyngealcancer
AT pawlitamichael accuracyofhighriskhpvdnapcrp16ink4aimmunohistochemistryorthecombinationofbothtodiagnosehpvdrivenoropharyngealcancer
AT tommasinomassimo accuracyofhighriskhpvdnapcrp16ink4aimmunohistochemistryorthecombinationofbothtodiagnosehpvdrivenoropharyngealcancer
AT arbynmarc accuracyofhighriskhpvdnapcrp16ink4aimmunohistochemistryorthecombinationofbothtodiagnosehpvdrivenoropharyngealcancer
AT accuracyofhighriskhpvdnapcrp16ink4aimmunohistochemistryorthecombinationofbothtodiagnosehpvdrivenoropharyngealcancer